Toxicology – Aminoglycoside Antimicrobials

Core Concept

Aminoglycosides are bactericidal antibiotics used mainly for serious infections caused by susceptible aerobic gram-negative organisms, often as part of combination therapy.

Important agents include:

• Gentamicin
• Tobramycin
• Amikacin
• Streptomycin
• Plazomicin
• Neomycin — mainly topical/oral nonabsorbed use
• Kanamycin — now rarely used in many settings

The major toxicities are:

• Nephrotoxicity
• Ototoxicity
• Rare neuromuscular blockade

Unlike many acute poisonings, clinically important aminoglycoside toxicity usually reflects repeated exposure or impaired clearance, rather than a single isolated dose.

Mechanism of Antimicrobial Action

Aminoglycosides enter susceptible bacteria and bind primarily to the 30S ribosomal subunit.

This disrupts protein synthesis through mechanisms including:

• Interference with initiation
• Misreading of mRNA
• Production of abnormal proteins

Their antibacterial activity is concentration dependent.

Toxicokinetics

Aminoglycosides are:

• Highly water soluble
• Poorly absorbed from the normal GI tract
• Distributed mainly in extracellular fluid
• Minimally metabolized
• Eliminated predominantly by the kidneys

Therefore:

Reduced renal function → decreased clearance → accumulation → increased toxicity

This is fundamental to aminoglycoside toxicology.

Acute vs Cumulative Toxicity

A single accidental dose, even if excessive, often does not produce the characteristic renal or auditory toxicity when baseline renal function is normal.

Greater concern arises with:

• Repeated excessive dosing
• Prolonged therapy
• Renal impairment
• Dehydration
• Critical illness
• Older age
• Concomitant nephrotoxins
• Persistently excessive systemic exposure

Thus, cumulative exposure is generally more informative than a single historical “toxic dose.”

1. Nephrotoxicity

Aminoglycosides accumulate within proximal renal tubular cells.

Intracellular accumulation causes cellular injury and can produce:

Proximal tubular injury → impaired renal function → acute kidney injury

The injury is usually nonoliguric initially, although more severe renal dysfunction can occur.

Clinical Features of Renal Toxicity

Possible findings include:

• Rising serum creatinine
• Reduced GFR
• Tubular dysfunction
• Electrolyte abnormalities

Importantly, renal injury usually develops after several days of exposure, rather than immediately after a single dose.

Reversibility

Aminoglycoside nephrotoxicity is often at least partially reversible after the drug is discontinued because tubular epithelium can recover.

However, severe AKI can require temporary renal replacement therapy.

Risk Factors for Nephrotoxicity

Important risk factors include:

• Preexisting kidney disease
• Prolonged therapy
• Excessive systemic exposure
• Older age
• Dehydration or hypovolemia
• Critical illness
• Sepsis
• Concurrent nephrotoxic medications

Nephrotoxic combinations deserve particular attention.

Other Nephrotoxic Drugs

Potentially important interacting exposures include:

• Vancomycin
• Amphotericin B
• Cisplatin
• Calcineurin inhibitors
• Other nephrotoxic medications

The total clinical context matters more than memorizing a single historical drug combination.

2. Ototoxicity

Aminoglycosides can damage sensory structures of the inner ear.

Toxicity may involve:

Cochlear system

→ hearing impairment

Vestibular system

→ disequilibrium/vertigo

Different aminoglycosides have somewhat different tendencies toward cochlear versus vestibular toxicity.

Cochlear Toxicity

Possible manifestations include:

• Tinnitus
• Reduced hearing
• Difficulty hearing high-frequency sounds
• Progressive sensorineural hearing loss

High-frequency hearing loss may occur before the patient recognizes impairment in ordinary conversation.

Vestibular Toxicity

Possible findings include:

• Dizziness
• Vertigo
• Disequilibrium
• Oscillopsia
• Gait instability

Severe bilateral vestibular injury may cause substantial chronic disability even without dramatic spinning vertigo.

Ototoxicity May Be Permanent

This distinguishes aminoglycoside ototoxicity from much of their renal toxicity.

Renal injury frequently improves after drug withdrawal.

In contrast:

Cochlear or vestibular damage may be irreversible.

Therefore, early recognition is important.

Delayed Ototoxicity

Auditory or vestibular injury may continue to become apparent even after therapy has stopped.

A normal bedside hearing assessment immediately after an exposure does not completely exclude evolving ototoxicity after significant cumulative treatment.

Genetic Susceptibility

Certain mitochondrial genetic variants, particularly involving MT-RNR1, can markedly increase susceptibility to aminoglycoside-associated hearing loss.

In susceptible individuals, significant ototoxicity may occur even with otherwise conventional therapeutic exposure.

This genetic susceptibility was underrecognized in older toxicology references.

3. Neuromuscular Blockade

Aminoglycosides can interfere with neuromuscular transmission.

Mechanisms include impaired presynaptic acetylcholine release and reduced neuromuscular transmission.

Severe toxicity may produce:

• Generalized weakness
• Reduced respiratory muscle strength
• Respiratory depression
• Apnea

This complication is uncommon but potentially life-threatening.

Risk Factors for Neuromuscular Blockade

Risk may increase with:

• High systemic concentrations
• Rapid parenteral administration
• Neuromuscular blocking drugs
• Myasthenia gravis
• Other neuromuscular disorders
• Electrolyte abnormalities
• Anesthesia

Aminoglycosides can potentiate pharmacologic neuromuscular blockade.

Neuromuscular Blockade – Management

The priority is:

Airway protection + ventilation when required + discontinue the offending drug

Modern management should not rely on physostigmine as a specific antidote.

The historical recommendation for physostigmine is not established contemporary treatment for aminoglycoside-induced neuromuscular blockade.

Specialist management may include correction of contributing electrolyte abnormalities and selected pharmacologic measures, but respiratory support is the critical intervention.

4. Oral Exposure

Most aminoglycosides are poorly absorbed from an intact gastrointestinal tract.

Therefore, an isolated accidental oral ingestion usually produces little systemic toxicity.

This is especially relevant to agents such as neomycin.

However, systemic absorption may become more significant when:

• GI mucosa is severely damaged
• Large or prolonged enteral exposure occurs
• Renal function is impaired

Topical Exposure

Topical aminoglycosides generally produce limited systemic absorption.

However, absorption can increase when applied extensively to:

• Large burns
• Open wounds
• Damaged mucosa
• Large body-surface areas

Repeated exposure can also produce contact sensitization, particularly with neomycin.

5. Hypersensitivity

Aminoglycosides may cause allergic reactions.

Manifestations can include:

• Rash
• Contact dermatitis
• Urticaria
• Rare severe immediate hypersensitivity

Neomycin is particularly well recognized as a cause of allergic contact dermatitis.

Therapeutic Drug Monitoring

The older fixed “toxic peak and trough” thresholds should not be treated as universal modern cutoffs.

Aminoglycoside monitoring depends on:

• Specific drug
• Dosing strategy
• Infection
• Renal function
• Duration of therapy
• Local pharmacokinetic protocol

Extended-interval dosing has changed how concentrations are interpreted.

Peak Concentration

Historically, peak concentrations were monitored to assess both efficacy and toxicity.

Modern practice recognizes that aminoglycosides exhibit concentration-dependent bacterial killing, so an appropriately high peak may actually be therapeutically desirable.

Therefore:

A high peak is not automatically synonymous with toxicity.

Interpretation depends on the agent and dosing strategy.

Trough Concentration

Persistent drug accumulation before subsequent doses is more concerning for toxicity.

Elevated trough or delayed clearance may indicate:

• Reduced renal elimination
• Excessive cumulative exposure
• Need for dose/interval adjustment

However, specific targets differ between drugs and treatment protocols.

Extended-Interval Dosing

Many patients now receive larger individual doses at longer intervals rather than traditional multiple-daily dosing.

This approach takes advantage of:

• Concentration-dependent killing
• Post-antibiotic effect
• Periods of very low drug concentration between doses

Consequently, old peak/trough values cannot simply be applied to every modern aminoglycoside regimen.

Diagnosis

Suspect aminoglycoside toxicity in a patient receiving one of these drugs who develops:

• Rising creatinine
• New hearing impairment
• Tinnitus
• Disequilibrium
• Vestibular dysfunction
• Unexpected weakness
• Respiratory compromise

Review:

• Drug
• Dose
• Dosing interval
• Duration
• Renal function
• Concentration data
• Other nephrotoxic/ototoxic drugs

Renal Evaluation

Important assessment includes:

• Serum creatinine
• BUN
• Electrolytes
• Urine output
• Serial renal function

Creatinine clearance/eGFR assists dosing assessment but must be interpreted cautiously during rapidly changing AKI because serum creatinine may lag behind true renal function.

Hearing Assessment

When ototoxicity is suspected, formal assessment may include:

• Audiometry
• High-frequency hearing evaluation
• Vestibular testing when indicated

Patients receiving prolonged high-risk therapy may benefit from baseline and follow-up hearing assessment.

Serum Aminoglycoside Concentrations

Drug concentrations can be clinically useful after:

• Significant parenteral dosing error
• Unexpected accumulation
• Renal impairment
• Prolonged therapy

Unlike many toxicologic drug concentrations, aminoglycoside levels can directly assist pharmacokinetic management.

Interpretation should account for the exact timing of blood sampling relative to the dose.

Initial Management

The general approach is:

Stop further exposure → assess renal function → obtain appropriately timed drug concentrations when useful → assess hearing/vestibular function → provide supportive care

Most single exposures in patients with normal renal function do not require aggressive treatment.

GI Decontamination

Because aminoglycosides are poorly absorbed orally, aggressive GI decontamination is generally unnecessary after an isolated oral exposure.

Do not induce vomiting.

Routine gastric lavage is obsolete.

Activated charcoal is generally of little practical value for most isolated aminoglycoside ingestions and should not be used routinely.

Hydration

Maintain appropriate intravascular volume and renal perfusion.

However, forced fluid administration does not “flush out” aminoglycosides and can cause volume overload.

Fluid therapy should therefore be guided by:

• Volume status
• Renal function
• Urine output
• Hemodynamics

Hypotension

Treat clinically significant hypotension with:

• Appropriate isotonic crystalloid when indicated
• Treatment of the underlying cause
• Vasopressor support if shock persists

Norepinephrine is generally favored for persistent vasodilatory shock.

Trendelenburg positioning and routine dopamine-first therapy are outdated.

Hemodialysis

Aminoglycosides have:

• Relatively low molecular weight
• Low protein binding
• Relatively small volume of distribution

Therefore, they are potentially dialyzable.

However, dialysis is usually unnecessary after a single overdose when renal function is normal because endogenous renal elimination is efficient.

When Dialysis May Become Relevant

Renal replacement therapy may be considered when there is:

• Severe renal failure with markedly impaired elimination
• Significant drug accumulation
• Serious toxicity with prolonged high concentrations
• Conventional renal indications such as severe electrolyte, acid–base, or volume abnormalities

The decision should be individualized with toxicology/nephrology input.

No Specific Antidote

There is no established specific antidote that reverses:

• Aminoglycoside nephrotoxicity
• Cochlear injury
• Vestibular injury

Management centers on preventing further exposure and providing organ support.

Differential Diagnosis – Acute Kidney Injury

Other causes of AKI include:

• Sepsis
• Shock
• Dehydration
• Rhabdomyolysis
• Urinary obstruction
• Other nephrotoxic medications
• Toxic alcohols
• Heavy metals

In critically ill patients, aminoglycosides may be only one of several simultaneous renal insults.

Differential Diagnosis – Hearing/Vestibular Symptoms

Consider:

• Other ototoxic medications
• Ear disease
• Vestibular neuritis
• Ménière disease
• Neurologic disorders
• Infection
• Age-related hearing loss

Other drugs with ototoxic potential can amplify risk.

Drug Interactions – Modern Perspective

The older interaction list should not be interpreted as a collection of absolute contraindications.

The clinically important principles are:

• Other nephrotoxins increase renal risk
• Other ototoxins may increase auditory/vestibular risk
• Neuromuscular blockers can have enhanced effects

Aminoglycosides and certain β-lactam antibiotics can also undergo chemical inactivation if physically mixed under inappropriate conditions, but this does not mean that clinically indicated combination therapy is universally prohibited.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Systemic aminoglycoside use during pregnancy requires assessment of:

• Maternal infection severity
• Specific aminoglycoside
• Alternative antibiotics
• Gestational circumstances
• Potential fetal ototoxicity

Serious maternal infection may make aminoglycoside therapy appropriate when benefits outweigh potential fetal risks.

Safeguarding

Rigid historical age cutoffs for assuming neglect, abuse, or intentional poisoning are inappropriate.

Pediatric exposures should instead be evaluated according to:

• Developmental capability
• Medication accessibility
• Exposure circumstances
• Consistency of history
• Recurrent unexplained events
• Broader safeguarding concerns

Monitoring

During significant exposure or therapeutic toxicity, monitor:

• Serum creatinine
• Renal function trend
• Urine output
• Electrolytes
• Appropriately timed aminoglycoside concentrations
• Hearing when indicated
• Vestibular function when symptomatic
• Respiratory status if weakness develops

Renal toxicity may not become apparent immediately, so follow-up should reflect the exposure pattern rather than an arbitrary short observation period.

Disposition

An isolated accidental oral exposure in an asymptomatic patient with normal renal function generally has low systemic toxicity.

Further evaluation or admission may be needed for:

• Significant parenteral dosing error
• Renal impairment
• Rising creatinine
• Persistent excessive drug concentrations
• Hearing loss
• Significant vestibular dysfunction
• Neuromuscular weakness
• Respiratory compromise
• Other serious complications

Prognosis

Renal toxicity

Often improves after discontinuation, although severe cases can require temporary dialysis.

Ototoxicity

May be permanent.

Neuromuscular blockade

Usually resolves as drug concentrations fall if adequate respiratory support is provided.

The most important strategy is prevention through appropriate dosing and renal monitoring.

Important Modernization of the Older Source

• Aminoglycoside toxicity is generally a cumulative exposure problem, not a classic single-dose overdose syndrome.
• The major toxicities remain nephrotoxicity and ototoxicity.
• Nephrotoxicity primarily reflects proximal tubular injury and is often reversible.
• Ototoxicity may involve cochlear or vestibular systems and can be permanent.
• MT-RNR1 mitochondrial variants can greatly increase susceptibility to aminoglycoside hearing loss.
• Aminoglycosides can rarely produce clinically important neuromuscular blockade.
• Physostigmine should not be considered a standard antidote for aminoglycoside neuromuscular toxicity.
• Fixed historical peak/trough “toxic levels” should not be applied indiscriminately to modern extended-interval dosing.
• Appropriately timed serum concentrations remain useful for therapeutic monitoring and significant dosing errors.
• Oral aminoglycosides are poorly absorbed, making most isolated oral overdoses low risk.
• Routine gastric lavage is obsolete, and activated charcoal generally has little role.
• Hemodialysis can remove aminoglycosides but is generally reserved for severe accumulation with impaired renal clearance or other dialysis indications.
• The historical statement that gentamicin/tobramycin should not be combined therapeutically with certain β-lactams is overly broad; physical incompatibility and pharmacokinetic issues should be distinguished from clinically useful combination therapy.
• Trendelenburg and routine dopamine-first shock treatment are outdated.
• Pregnancy should no longer be described using the old FDA letter categories.

Key Points

• Aminoglycosides → kidney + inner-ear toxicity.
• Nephrotoxicity = proximal tubular injury and AKI.
• Ototoxicity = cochlear hearing loss and/or vestibular dysfunction.
• Kidney injury is often reversible; hearing or vestibular damage may not be.
• Toxicity is usually associated with repeated exposure, accumulation, or renal impairment.
• A single accidental oral ingestion usually has low systemic toxicity because GI absorption is poor.
• Renal impairment markedly prolongs elimination.
• Serum concentrations are useful when interpreted according to the specific dosing strategy.
• Rare severe toxicity can cause neuromuscular weakness and respiratory failure.
• There is no specific antidote.
• Management centers on stopping exposure, monitoring renal and auditory function, supportive care, and selected dialysis when clearance is severely impaired.